Company
GlaxoSmithKline
GlaxoSmithKline has 82 drugs tracked on RxWires: 9 post-market, 7 approved, 21 in Phase 3, 1 in Phase 2/3, 23 in Phase 2, 5 in Phase 1/2, 16 in Phase 1.
- Ticker
- GSK
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Engerix™-B | Post-Market | Hepatitis B |
| BENZOYL PEROXIDE/ CLINDAMYCIN | Post-Market | Acne Vulgaris |
| valacyclovir hydrochloride | Post-Market | Herpes Genitalis |
| Dutasteride | Post-Market | Hypogonadism |
| Umeclidinium | Post-Market | Pulmonary Disease, Chronic Obstructive |
| fluticasone furoate nasal spray | Post-Market | Rhinitis, Allergic, Perennial |
| Ofatumumab | Post-Market | Leukaemia, Lymphocytic, Chronic |
| ROP | Post-Market | Parkinson Disease |
| Mepolizumab | Post-Market | Asthma |
| BACTOCILL | Approved | |
| EPIVIR-HBV | Approved | |
| FLUTICASONE FUROATE ELLIPTA | Approved | |
| SUMATRIPTAN | Approved | |
| VONTROL | Approved | |
| LANOXICAPS | Approved | |
| HIBSAGO | Approved | |
| Retigabine | Phase 3 | Seizures |
| RSVPreF3 OA investigational vaccine | Phase 3 | Respiratory Syncytial Virus Infections |
| GSK5784283 | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| rMenB+OMV NZ vaccine | Phase 3 | Meningitis |
| Efimosfermin alfa | Phase 3 | Metabolic Dysfunction-associated Steatohepatitis |
| RSVPreF3 OA vaccine | Phase 3 | Respiratory Syncytial Virus Infections |
| Quadrivalent seasonal influenza vaccine GSK2282512A | Phase 3 | Influenza |
| GSK573719/GW642444 Inhalation Powder | Phase 3 | Pulmonary Disease, Chronic Obstructive |
| TREXIMET® | Phase 3 | Migraine Disorders |
| DTG + 3TC | Phase 3 | HIV Infections |
| Dexamethasone | Phase 3 | Cancer |
| lamotrigine, 300 mg/day | Phase 3 | Epilepsy, Partial |
| Diclofenac diethylamine 2.32% gel | Phase 3 | Pain |
| GSK580299 (Cervarix) | Phase 3 | Infections, Papillomavirus |
| GSK2402968 | Phase 3 | Muscular Dystrophies |
| clindamycin / benzoyl peroxide gel | Phase 3 | Acne Vulgaris |
| Fluviral® | Phase 3 | Influenza |
| FF/UMEC/VI | Phase 3 | Asthma |
| Herpes Zoster Vaccine GSK1437173A | Phase 3 | Herpes Zoster |
| Dostarlimab | Phase 3 | Lung Cancer, Non-Small Cell |
| Risvutatug rezetecan (Ris-Rez) | Phase 3 | Neoplasms, Lung |
| Experimental paracetamol + caffeine formulation | Phase 2/3 | Headache, Tension-Type |
| Pagibaximab (formerly BSYX-A110) | Phase 2 | Staphylococcal Sepsis |
| Daplusiran/Tomligisiran Dose Level 1 | Phase 2 | Chronic Hepatitis B Virus Infection |
| AltSonflex1-2-3 | Phase 2 | Diarrhoea |
| Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Phase 2 | Influenza |
| GW842166 | Phase 2 | Osteoarthritis, Knee |
| Naproxen | Phase 2 | Osteoarthritis |
| GW685698X | Phase 2 | Asthma |
| GSK256066 | Phase 2 | Rhinitis, Allergic, Seasonal |
| 250mg rilapladib | Phase 2 | Alzheimer's Disease |
| Pembrolizumab | Phase 2 | Lung Cancer, Non-Small Cell |
| GSK189075 | Phase 2 | Diabetes Mellitus, Type 1 |
| Lapatinib Vinorelbine | Phase 2 | BRMS1 |
| GSK3145095 | Phase 2 | Neoplasms, Pancreatic |
| Sodium fluoride | Phase 2 | Tooth Erosion |
| FluLaval® Quadrivalent | Phase 2 | Influenza |
| Belantamab Mafodotin | Phase 2 | Relapsed Plasmablastic Lymphoma |
| GSK256073 | Phase 2 | Dyslipidaemias |
| ezogabine/retigabine | Phase 2 | Epilepsy |
| IONIS-HBVRx | Phase 2 | Hepatitis B |
| GSK3772701 600 mg | Phase 2 | Malaria, Falciparum |
| CV0701 mRNA COVID-19 Vaccine (Low dose) | Phase 2 | SARS-CoV-2 |
| Lapatinib | Phase 2 | Neoplasms, Breast |
| SB-649868 | Phase 2 | Sleep Initiation and Maintenance Disorders |
| GSK5471713 | Phase 1/2 | Neoplasms, Prostate |
| 40 µg gE-gI | Phase 1/2 | Herpes Simplex |
| F2C22C/DL001Z | Phase 1/2 | Influenza, Human |
| temozolomide | Phase 1/2 | Pancreatic Alpha Cell Carcinoma |
| MenABCWY-2Gen low dose vaccine | Phase 1/2 | Infections, Meningococcal |
| SB773812 | Phase 1 | Schizophrenia |
| Pazopanib | Phase 1 | Neoplasms, Colorectal |
| GSK561679 tablet or solution | Phase 1 | Healthy Subjects |
| GSK3862995B | Phase 1 | Pulmonary Disease, Chronic Obstructive |
| Salbutamol HFA-152a | Phase 1 | Asthma |
| Reference formulation | Phase 1 | Prostatic Hyperplasia |
| topotecan | Phase 1 | Cancer |
| GSK1349572 | Phase 1 | Infection, Human Immunodeficiency Virus |
| GSK1322322 Initial fit for purpose tablets | Phase 1 | Infections, Bacterial |
| GSK4382276A Dose level 1 | Phase 1 | Influenza, Human |
| GSK2190915 100mg milled tablet | Phase 1 | Asthma |
| Zanamivir | Phase 1 | Influenza, Human |
| CV2CoV (2 µg) | Phase 1 | COVID-19 |
| Relacatib | Phase 1 | Osteoarthritis |
| GSK6097608 | Phase 1 | Neoplasms |
| Diclofenac Diethylamine (DDEA) gel | Phase 1 | Pain |
Latest
- Exclusivity ends 2026-03-01 (application 205625)
- glaxosmithkline filed 6-K
- HIBSAGO approved by FDA
Follow GlaxoSmithKline on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.